Needham & Company LLC reissued their buy rating on shares of Generation Bio (NASDAQ:GBIO – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $10.00 price target on the stock.
Separately, Wedbush restated an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research report on Thursday, August 8th.
Check Out Our Latest Stock Report on Generation Bio
Generation Bio Trading Down 4.7 %
Generation Bio (NASDAQ:GBIO – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The firm had revenue of $4.09 million during the quarter, compared to analyst estimates of $3.23 million. Generation Bio had a negative net margin of 1,202.56% and a negative return on equity of 92.86%. On average, research analysts predict that Generation Bio will post -1.8 EPS for the current fiscal year.
Hedge Funds Weigh In On Generation Bio
Institutional investors have recently added to or reduced their stakes in the stock. PFG Advisors acquired a new position in Generation Bio during the 1st quarter worth approximately $41,000. SG Americas Securities LLC acquired a new position in Generation Bio during the 3rd quarter worth approximately $42,000. Cubist Systematic Strategies LLC increased its position in Generation Bio by 91.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company’s stock worth $54,000 after purchasing an additional 9,075 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Generation Bio during the 1st quarter worth approximately $74,000. Finally, American Century Companies Inc. increased its position in Generation Bio by 199.3% during the 2nd quarter. American Century Companies Inc. now owns 31,786 shares of the company’s stock worth $90,000 after purchasing an additional 21,167 shares in the last quarter. 95.22% of the stock is currently owned by institutional investors and hedge funds.
About Generation Bio
Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.
Featured Articles
- Five stocks we like better than Generation Bio
- How to invest in marijuana stocks in 7 stepsĀ
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Ride Out The Recession With These Dividend KingsĀ
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Calculate Options Profits
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.